Lentinula edodes is one of the most widely used medicinal mushrooms which exhibit significant antitumor activity. It is mostly studied and several studies have showed that its polysaccharides play critical roles in the antitumor effects. In this study, we determine the antitumor activity of Lentinula edodes 
INTRODUCTION
Lentinula edodes, commonly known as the Shiitake mushroom, is the second most popular and widely cultivated edible mushroom in the world. As the main medicinal fungi, its extract has anti-viral, anti-bacteria, anti-tumor activity and regulation of immune function, etc (Hearst et al., 2009; Kuppusamy et al., 2009; Sarangi et al., 2006; Unursaikhan et al., 2006) . The strain of Lentinula edodes was studied in March, 1991. So we named Lentinula edodes C 91-3 , and "C" means China. Numerous studies showed Lentinan could inhibit tumor cells growth, improve patient's symptoms, and reduce adverse reactions. It is now officially used for clinical medicine as adjuvant chemotherapy drugs (Ooi and Liu, 2000; Kidd, 2005; Zheng et al., 2005; Fang et al., 2006; Miyaji et al., 2006) . However, antitumor activity of Lentinula edodes on protein level was rarely reported. In this study submerged fermentation for Lentinula edodes C 91-3 mycelia was done and its antitumor effects on protein level were determined. *Corresponding author. E-mail: huangminchao@163.com. Tel:+86-411-86110007. Fax: +86-411-86110007
MATERIALS AND METHODS

Experimental animals
50 healthy inbred BALB/C mice were selected. Three months old SPF-grade mice were used having weight 18 to 20 g. We used 20 male and 20 female mice, obtained from the Experimental Animal Center of Dalian Medical University. This study was approved by Dalian Medical University Animal Ethical Review Committee, similar to the guidelines for the use and care of animals that are published by the National Institute of Health.
Carcinoma cell lines
S180 (mouse sarcoma tumor) cell lines were obtained from the Department of Microbiology of Dalian Medical University. Cell lines were grown in RPMI-1640 medium (Gibco) containing 10% fetal calf serum (China National Medicines Corporation, Ltd). The cells were incubated at 37°C in a humidified atmosphere containing 5% CO2.
Lentinula edodes C91-3 strain and culture conditions
Lentinula edodes C91-3 strain were obtained from the Department of Microbiology of Dalian Medical University. It was cultured in the potato culture medium containing 1% Vitamin B1, 2.0% Agar, 0.15% MgSO4, 0.3% K2HPO4, and 2.0% glucose having pH 6.0. 
Extraction of Lentinula edodes C91-3 fermentation protein
Lentinula edodes C91-3 was inoculated in the sterile liquid medium containing 10 g/L glucose, 5 g/L yeast extract, peptone 1.0 g/L, vitamin B1 0.01 g/L, vitamin B2 0.01 g/L, and 1.0 g/L KH2PO4 in a 5 L bioreactor at 35°C, pH 6.5 at120 rpm, with air flow rate of 3 L/min for 7 days, and then continued fermenting at 25°C. When number of spores achieved 10 7 /ml, the broth was collected and centrifuged for 10 min with 3,000 g/min at 4°C condition. The supernatant was collected and filtered through sterile filter paper (Size of filter). LFP91-3 from filtration liquid were gained through salting out with (NH4)2SO4 and then dialyzed with sterile distilled water. The protein samples were freeze dried and stored at 4°C till use.
Antitumor activity on S180 tumor-bearing mice in vivo
The S180 ascitic tumor cell number and viability were determined, and then cell concentration was adjusted to 1×10 7 cells per ml with complete RPMI 1640 medium. The inbred BALB/c mice were inoculated with 1 ml tumor cells by intra-peritoneal injection. After 24 h, we established S180 ascitic tumor cells randomly in mice (n=50) and divided the mice into five groups of 10 each: 1) normal saline (NS) control, 2) cyclophosphamide (CTX) group, 3) LFP91-3I-treatment group, 4) LFP91-3II-treatment group, and 5) LFP91-3 IIItreatment group. The tumor-bearing in NS control group were injected intra-peritoneal with NS 1 ml, once daily for 5 days, CTX group to cyclophosphamide 0.4 mg, LFP91-3Ⅰ group to LFP91 to 3 50 µg, LFP91-3Ⅱ Group to LFP91-3 100 µg; LFP91-3Ⅲ group to LFP91-3 150 µg. The dose, means, methods and frequency of injection were the same as the NS group. The growth rates and survival times of tumor-bearing mice were determined in the five groups. From these values, we calculated the viability of tumor-bearing mice that survived for a minimum of 60 days.
Antitumor test of LFP91-3 on S180 tumor cell through MTT (sigma) assay in vitro
The effect of LFP on S180 tumor cells was determined using the 3-(4, 5-dimethylthiazol-2-yl)-2, 5-diphenyltetrazolium bromide (MTT) assay (Carmichael et al., 1987) . S180 cells in the logarithmic phase were selected, and the cell survival rate was >95%, as determined by trypan blue staining. The cell concentration was adjusted to a final concentration of 5×10 6 cells per ml. and then 100 μl was added into 96-well plate per hole. After pre-incubating S180 tumor cells for 8 h at 37°C in 5% CO2 incubator, the control group was added NS 100 μl. 100 μl of LFP91-3 (5, 10 and 15 µg/ml) with different concentrations was added as the experimental group and incubated with the cells for 24, 48 and 72 h. 20 μl of the MTT stock solution (5 mg/ml) was added to each well and incubated for 4 h, and the plate was centrifuged at 800×g for 5 min and the supernatants were aspirated. The formazan crystals in each well were dissolved in 150 μl dimethylsulfoxide and then absorbance at 540 nm was measured on scanning multiwell spectrophotometer. The tumor inhibition ratio was calculated as follows:
Inhibition ratio = (1 -A540 in experimental group / A540 in control group) × 100%.
Apoptosis detection of LFP91-3 on S180 cell through flow cytometry in vitro S180 cells in the logarithmic phase were selected, and the cell survival rate at >95%, was determined by trypan blue staining. The cell concentration was adjusted to a final concentration of 1×10 7 cells per ml. 100 μl cell suspension was added into 96-well plate per well. After pre-incubating S180 tumor cells for 8 h at 37°C in 5% CO2 incubator, the control group contains normal saline 100 μl. 100 μl LFP91-3 with a final concentration (5 μg/ml) was added as the experimental group and incubated with the cells for 24, 48 and 72 h. The cells were collected and the cell concentration was adjusted to 5 × 10 5 /ml. The cells were washed twice with PBS, centrifuged at 1000 rpm for 5 min and the supernatants were aspirated. The cells were suspended with 500 μl 1× Binding Buffer, followed by adding 5 μl Annexin V-FITC, 5 μl PI (BioVision Annexin V-FITC Apoptosis Detection Kit), keep in dark for 5min at room temperature, and then detected through flow cytometry.
Statistical analyses
The data were analyzed by ANOVA using SPSS software. Results are reported as mean ± standard deviation and p<0.05 was set as statistical significance.
RESULTS
Survival
The tumor visibly increased in size, and survival time decreased in the S 180 tumor-bearing mice. We observed peritoneal swelling in the NS-control group by the seventh day after inoculation, and mortality was 100%, with an average survival time of 15.8 days (Table 1 ). In the CTX group, mortality was 100%, with an average survival time of 21.3 days (5.5 days longer than the control group; p<0.05). In the LFP 91-3 I-treatment group, mortality was 80%, with an average survival time of 23.0 days (7.2 days longer than the control group; p <0.05). In Figure 1 . Inhibition ratio of S180 cell growth affected by different concentration LFP91-3. Table 2 . Inhibition ratio of S180 cell growth affected by different concentration LFP91-3.
Time (h)
Inhibition ratio (%) 5 μg/ml 10 μg/ml 15 μg/ml the LFP 91-3 II-treatment group, in contrast, mortality was only 60%, with an average survival time of 28.5 days (12.7 days longer than the control group; p <0.05). In the LFP 91-3 III-treatment group, mortality was 50%, with an average survival time of 33.6 days (17.8 days longer than the control group; p <0.05). However, the survival time of tumor-bearing mice was depended the certain dose of LFP 91-3 .
Growth-inhibiting effect on S 180 cell line by LFP 91-3
It can be seen from Figure 1 and Table 2 , LFP 91-3 could inhibit S 180 cell growth directly, and its intensity and effectiveness depended on certain range of concentration and time.
Apoptosis analysis of S 180 cell induced by LFP 91-3
The apoptosis with a significant increase in the initial stage effected by LFP 91-3 (5 μg/ml) on S180 cells was 5.56% in 24 h, 7.51% in 48 h, 8.47% in 72 h (Table 3 and Figure 2D , E and F); and the apoptosis in NS control group was 0.82% in 24 h, 0.93% in 48 h, 1.22% in 72 h (Table 3 , Figure 2A , B, and C). It was obviously that LFP91-3 experimental group was significantly higher than NS control group (P<0.05) Figure 3 . due to malignant tumors (Ebina, 2005) . The studies on anti-tumor ingredients extracted from the fungus or its metabolites have increased researchers attention. Its antitumor activity has been recognized internationally. But there were many research have been done about polysaccharide extracts from Lentinula edodes (Borchers et al., 2004; Ooi and Liu, 2000; Kidd, 2005; Zheng et al., 2005; Fang et al., 2006; Miyaji et al., 2006; Ng and Yap, 2002) . To explore its antitumor activity on protein level, we firstly found that the LFP 91-3 gained through submerged fermentation could kill S 180 tumor cells directly in vitro, and its mechanism related to apoptosis pathway induced by LFP . In vivo, LFP 91-3 extended the life span of S 180 tumor-bearing mice, but the mechanism needs to be further study. However, LFP 91-3 was crude protein complexes. So further research will focus on the structure and biochemical character of protein monome and study the anti-tumor mechanism on apoptosis pathway in detail.
DISCUSSION
In conclusion, our study provides a new kind of antitumor material and a new theoretical basis for further study of the mechanism in antitumor proteins from Lentinula edodes C 91-3 Mycelia Fermentation Protein.
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